DRIO — DarioHealth Corp.

Summary of DarioHealth Corp. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $5.2 million, with a full-year revenue of $22.4 million, down from $27.0 million in 2024, primarily due to the non-renewal of a legacy client.
• Annual Recurring Revenue (ARR): $12.9 million in contracted and late-stage ARR for 2026 and 2027.
• Gross Margin: Improved from 49% in 2024 to 57% in 2025, with the core B2B2C business maintaining an 80% non-GAAP gross margin.
• Operating Expenses: Total operating expenses decreased by 31% to $49.3 million in 2025, with Q4 operating expenses at $11.4 million, down 28% year-over-year.
• Cash Position: Ended 2025 with $26.0 million in cash and short-term deposits, with a 33% reduction in net cash used in operating activities.

2. Strategic Updates and Business Highlights

• New Agreements: Signed 85 new agreements in 2025, significantly exceeding the target of four, with contract sizes 2 to 10 times larger than historical averages.
• Market Positioning: Focus on multi-condition digital health solutions is gaining traction, with nearly 80% of the commercial pipeline involving multi-condition deployments.
• Channel Partnerships: Expanded distribution through partnerships with major payers and health plans, including Florida Blue and UnitedHealthcare, providing access to over 160 million covered lives.
• AI Integration: Leveraging AI capabilities through DarioIQ, which is trained on over 13 billion data points, enhancing competitive positioning.

3. Forward Guidance and Outlook

• Revenue Growth: Expected to continue in 2026, with the second half anticipated to show the strongest acceleration.
• Operating Loss Reduction: Targeting a 30% reduction in non-GAAP operating loss in 2026, with a goal of reaching cash flow breakeven by mid-2027.
• Pipeline Value: Current commercial pipeline valued at $122 million, indicating strong future revenue visibility.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The overall revenue decrease in 2025 was attributed to the loss of a single legacy client, which raises concerns about dependency on existing contracts.
• Breakeven Timeline: The timeline for achieving cash flow breakeven has been pushed out, with management indicating that growth is the primary driver for this delay.
• Operational Adjustments: Transitioning to a one-to-many distribution model requires adjustments in operations, which may introduce temporary inefficiencies.

5. Notable Q&A Insights

• Revenue Growth Cadence: Management expressed confidence in achieving revenue growth in 2026, with expectations for acceleration in the latter half of the year.
• Operating Expenses: Continued focus on reducing operating expenses while optimizing for growth, with AI expected to contribute to further cost reductions.
• Market Capture Strategy: Discussions highlighted the preferred partner status within health plan networks, which could facilitate easier access to large populations, although the capture rate remains uncertain.
• Pipeline Clarification: The increase in pipeline value includes opportunities for both 2026 and 2027, reflecting a broader view of future potential.

Overall, DarioHealth Corp. demonstrated strong strategic momentum in 2025, despite facing challenges related to revenue declines from legacy clients. The company is well-positioned for growth through its innovative platform and expanding partnerships, with a clear focus on achieving operational efficiencies and revenue growth in the coming years.